634 related articles for article (PubMed ID: 22128299)
1. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
2. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
[TBL] [Abstract][Full Text] [Related]
3. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
4. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM
Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458
[TBL] [Abstract][Full Text] [Related]
5. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
[TBL] [Abstract][Full Text] [Related]
6. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
7. N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Bruno S; Ghiotto F; Tenca C; Mazzarello AN; Bono M; Luzzi P; Casciaro S; Recchia A; Decensi A; Morabito F; Fais F
Leukemia; 2012 Oct; 26(10):2260-8. PubMed ID: 22475870
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
Rooswinkel RW; van de Kooij B; Verheij M; Borst J
Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Huelsemann MF; Patz M; Beckmann L; Brinkmann K; Otto T; Fandrey J; Becker HJ; Theurich S; von Bergwelt-Baildon M; Pallasch CP; Zahedi RP; Kashkar H; Reinhardt HC; Hallek M; Wendtner CM; Frenzel LP
Leukemia; 2015 Apr; 29(4):981-4. PubMed ID: 25376373
[No Abstract] [Full Text] [Related]
11. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2high/Mcl-1low profile and synergizes with other antineoplastic agents.
Touzeau C; Dousset C; Bodet L; Gomez-Bougie P; Bonnaud S; Moreau A; Moreau P; Pellat-Deceunynck C; Amiot M; Le Gouill S
Clin Cancer Res; 2011 Sep; 17(18):5973-81. PubMed ID: 21821698
[TBL] [Abstract][Full Text] [Related]
12. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
Hallaert DY; Jaspers A; van Noesel CJ; van Oers MH; Kater AP; Eldering E
Blood; 2008 Dec; 112(13):5141-9. PubMed ID: 18796631
[TBL] [Abstract][Full Text] [Related]
13. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
[TBL] [Abstract][Full Text] [Related]
14. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
Soderquist R; Pletnev AA; Danilov AV; Eastman A
Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
[TBL] [Abstract][Full Text] [Related]
15. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE
Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
[TBL] [Abstract][Full Text] [Related]
16. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1.
Yecies D; Carlson NE; Deng J; Letai A
Blood; 2010 Apr; 115(16):3304-13. PubMed ID: 20197552
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
18. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
[TBL] [Abstract][Full Text] [Related]
19. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
[TBL] [Abstract][Full Text] [Related]
20. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.
Tahir SK; Yang X; Anderson MG; Morgan-Lappe SE; Sarthy AV; Chen J; Warner RB; Ng SC; Fesik SW; Elmore SW; Rosenberg SH; Tse C
Cancer Res; 2007 Feb; 67(3):1176-83. PubMed ID: 17283153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
